The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.
Eleftherios P. Mamounas
Consultant or Advisory Role - Genomic Health
Honoraria - Genomic Health
Gong Tang
No relevant relationships to disclose
Soonmyung Paik
No relevant relationships to disclose
Frederick L. Baehner
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Qing Liu
No relevant relationships to disclose
Jong-Hyeon Jeong
No relevant relationships to disclose
Seong-Rim Kim
No relevant relationships to disclose
Steven M Butler
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Farid Jamshidian
Employment or Leadership Position - Genomic Health
Diana B. Cherbavaz
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Thomas B. Julian
No relevant relationships to disclose
Barry C. Lembersky
Stock Ownership - Genomic Health
D. Lawrence Wickerham
No relevant relationships to disclose
Joseph P. Costantino
No relevant relationships to disclose
Norman Wolmark
No relevant relationships to disclose